Optimizing chemical structures to create potentially safe drugs during discovery and early development relies on a combination of predictive algorithms, screening, formal toxicology studies, and early clinical trials. Early in the process three critical questions emerge that must be answered by a detailed "profiling" approach. These questions are: 1) is there a correlation between the chemical structure and potential toxicity that can be used to optimize structures of lead compounds, 2) can specific markers of potential toxicity can be identified early and used as mechanistic decision-making screens, and 3) will exposures (plasma levels) in animal studies correlate with exposures encountered in the clinic thereby providing "coverage" for safety? Depending on the therapeutic class of compounds being considered and the level of knowledge available, feedback loops of information can be established to guide the development process.
INTRODUCTION
Early assessments of the potential toxicity of new pharmaceuticals are multi-dimensional tasks, involving predictive systems, screening approaches, and animal studies to aid in the optimization of lead compounds prior to entering development. These assessments continue through the early phases of development where decisions are made to stop or continue a project or replace the candidate drug with an optimized back-up compound. Knowledge bases can be developed throughout the R&D process and used to facilitate decision-making based on predicted risk assessment relevant to targeted patient populations as suggested in (Fig. 1) . Information systems provide a feedback mechanism whereby "old" information can be used to support new discovery and development projects. The most difficult task is predicting or estimating margins of safety -the ratio of the dose causing toxicity to the dose eliciting efficacy -as these estimates still require in vivo information to be developed on individual lead compounds.
In this review, we will discuss the overall scheme of how drugs are assessed for toxicity by highlighting key points from international guidelines, general schemes for development as followed by a majority of pharmaceutical companies, and approaches used in early discoverydevelopment to move drugs into the development pipeline faster. As a method of illustration we will focus on predictive algorithms used for optimizing exposure in laboratory animals to facilitate clinical trials and newer screening approaches to assess potential toxicity in certain target organs. Since drugs fail in development because of toxicity for several reasons [1] including both animal and human toxicities, we will highlight this discussion using examples where the toxicity (renal) would represent serious adverse events in human subjects.
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DRUG DEVELOPMENT SCHEMES
The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines [2] can be abbreviated into two main categories in order to illustrate the regulatory requirements for safety assessment for new pharmaceuticals, specifically synthetic molecules, during drug development. These categories are: 1) studies supporting various phases of clinical trials (e.g. Phase I, II, or III) and 2) the duration of animal studies required to support the clinical trials of a certain length.
Requirements prior to human exposure (Phase I)

Safety pharmacology Single dose toxicity in 2 species
Repeat dose studies in 2 species Exposure in animal species (toxicokinetics) Local tolerance (if applicable) Genotoxicity (in vitro tests)
Male fertility (Japan only)
Additional studies required prior to Phase II ADME studies Genotoxicity -complete full battery including in vitro studies
Specific requirements for duration of repeat dose studies
The majority of pharmaceutical companies will superimpose the Guidelines (as shown above) onto a decision-making grid that approximates a timescale of events leading to drug approval. For toxicology, the timescale can be divided into:
Early Discovery Support: computational and screening toxicology for lead identification and lead optimization The major difference between companies is when the decision is made to pursue full development, which will trigger full-scale process chemistry decisions and expenditures. In some companies, this occurs when a development candidate (the candidate drug) is selected, in others when all IND (Investigational New Drug Application) work has been completed. Alternatively, some companies defer these decisions until preliminary clinical information (e.g. pharmacokinetics, surrogate markers of activity) suggests increased probability of success. Regardless of the decision-making scheme, key questions must be answered early. These include: 1) is there a correlation between the chemical structure and potential toxicity that can be used to optimize structures of lead compounds, 2) can specific markers of potential toxicity can be identified early and used as mechanistic decision-making screens, and 3) will exposures (plasma levels) in animal studies correlate with exposures encountered in the clinic thereby providing "coverage" for safety? Since exposure considerations are critical during development activities, there is usually a need to optimize bioavailability in early toxicology studies so that more accurate predictions of exposure and differences in the internal dose (e.g. Cmax, AUC) between species can be fully understood as early in the development scheme as possible. Developing this information early can lead to making accurate predictions of compound needs for future studies and help in understanding differences in response between species.
CORRELATION BETWEEN CHEMICAL STRUC-TURE AND POTENTIAL TOXICITY
The authors have recently reviewed newer approaches for predicting the potential toxicity of drugs in discovery and development using a combination of computational methods and mechanistic in vitro and in vivo screening [3] . A Tier approach for predictive screening can be viewed as follows: 
Advanced Testing
Establish development candidate (product alert) selection criteria and screen lead compounds to select development candidate
In vivo testing in relevant animal species
In another recent review, we have described a chemoinformatics approach for correlating chemical structure with toxicity oriented towards defining the descriptors of the problem space in medicinal chemistry building blocks, thereby allowing chemists to optimize lead structures via specific sub structural features easily adaptable to combinatorial chemistry technologies [4] . This will not be repeated in this review, but rather we will expand on how the collection of information during discovery and early development can provide a feedback loop to generate the information necessary to make predictive systems work. Focusing on early information used to make decisions that affect the optimization of leads or back-up compounds will highlight the remaining content of this review.
MARKERS OF POTENTIAL TOXICITY AND MECHANISTIC SCREENING
In any screening program, where the goal is to identify certain potential toxicological characteristics shared by a group of related chemicals, it is important to establish relevant markers of toxicity (toxicodynamic markers) that can be used for screening purposes. In some instances, a general scheme of screening can be established based on common cellular targets of known toxicants; a proposed scheme is shown in (Fig. 2) . In other instances, markers of toxicity of specific target organs are used. Establishing markers of renal toxicity offers a good example of the complexity involved in establishing clear mechanistically based screening processes.
The kidney is a common target organ of toxicity following exposure to many classes of pharmaceutical agents including analgesics, antibiotics, antineoplastics, immunosuppressive agents and radiocontrast agents. Numerous toxicodynamic markers exist for assessing renal toxicity in vivo including serum markers such as blood urea nitrogen (BUN) and creatinine, standard urinalysis, specific urinary enzymes and proteins, and renal function tests [5] . While research has been ongoing in the areas of metabonomics, toxicogenomics and proteomics for some time now, these techniques and the markers they define are at the point they can begin to be applied in drug discovery and development.
Metabonomics combines high resolution
1 H NMR with pattern recognition to evaluate the metabolic state of an animal. Using non-invasive samples such as urine, the target organ can be determined as well as the onset, duration and severity of the insult. The application of data analysis techniques such as principal components analysis [6] and probabilistic neural networks [7] have enabled researchers to more efficiently and accurately determine patterns and improve the likelihood of finding meaningful biomarkers. A recent paper by Robertson et al [6] demonstrates the utility of this technique in discriminating renal and hepatic toxins and points out how metabanomics is applicable to rapidthroughput in vivo screening. In a study using 13 model toxins affecting primarily the liver and kidney, Holmes at al [7] showed they could distinguish affected organ, the site of injury, and even strain differences in rats. Clinical applications of this technology are also being pursued as a way to limit toxicity and optimize therapy. For example, the ratio of the urinary excretion of mesna to dimesna appears to correlate to the degree of ifosfamide-induced renal toxicity [8] . In the future, markers such as these could be used to individualize treatment. 
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Correlation with in vivo studies Additional mechanistic studies
Fig. (2). In vitro/ex vivo screens based on common cellular targets of toxicants
Proteomics, or the characterization of protein patterns, have been used to examine the differential expression of cortical and medullary proteins in rat kidney [9] . These investigators found 127 proteins that differed in abundance between the two regions and 30 proteins that were unique to one region or the other. Lead, a nephrotoxin and renal carcinogen, was shown to alter the abundance of 76 proteins in the cortex and 13 in the medulla [10] . While specific protein biomarkers for renal toxicity are not well characterized, this should be feasible as demonstrated by Aicher et al [11] who used two-dimentional gel electrophoresis to discover calbindin-D 28kDa, a possible marker for cyclosporine nephrotoxicity. Large scale application of proteomics should be on the horizon with advances in technology and the advent of protein microarrays [12, 13] .
The use of gene expression transcript profiling holds great promise for determining mechanisms of target organ injury and selecting valuable markers of such injury. To date, the liver has been the focus of most of the research. Profiles are being established with known classes of hepatotoxicants in the hope that these profiles can then be referenced when profiling novel compounds [14, 15] . Microarray techniques, either commercial or in-house custom arrays, are being established or used in most pharmaceutical companies. The concept of gene expression profiling is the same for all target organs and data are now emerging for other organs including kidney [16] .
While these techniques will be commonly used in the future, some issues remain. All of the techniques require relatively expensive equipment or supplies; e.g. a high resolution NMR for metabonomics, mass spectrometer(s) for protein identification and microarrays for toxicogenomics. Improvements in microfluidics and chip manufacturing, system automation, faster analysis and automated sample preparation should decrease cost in the not too distant future. In order for these techniques to be successful for screening, mechanistic determinations and identification of biomarkers, information management and development of well-annotated databases are critical.
In vitro systems provide a more controlled environment to conduct mechanistic studies and have an advantage of ease of use and low cost for screening purposes. Numerous renal systems have been developed including isolated perfused kidney, isolated nephron segments (glomeruli, proximal tubules), tissue slices, primary cells and continuous cell lines [17, 18] . A relatively large database exists for several classes of known nephrotoxic drugs and establishing the in vitro/ in vivo correlations for these known agents has helped to validate these systems as screening tools. Parameters commonly used to measure cellular responses include electrolyte homeostasis, enzyme leakage, energy status, neutral red uptake, MTT conversion, protein RNA/DNA synthesis, tubular transport, gene expression and morphology.
The goal of these screening techniques in drug discovery and development is usually to select less toxic leads in a series of analogs. LLC-PK1 cells, an established epithelial line derived from porcine proximal tubules, have been used extensively for these purposes. Successful ranking of aminoglycosides and cephalosporin antibiotics have been shown in LLC-PK1 cells [19, 20] where the rank order in the in vitro system correlated with in vivo findings [21] . However, use of these systems to screen unknown classes of compounds is less successful when little is known about structure-activity relationships and metabolism of similar compounds [22] .
Although cell lines offer technical simplicity and thus higher throughput, they may lack physiologic characteristics of the target organ cell types. In order to have a better representation of the cell characteristics in vivo, primary cultures and tissue slices have been employed. Because these systems require animals to derive cultures and can be more technically demanding than continuous cell lines, these models are used most often for mechanistic research or comparing small numbers of lead compounds. Similar markers of functional alterations (transport, macromolecule synthesis, energy status) and cytotoxicity (enzyme leakage, potassium loss) are used for primary cultures and cell lines. Primary cultures and slices can be obtained from a variety of species including mouse, rat, rabbit, pig, dog, monkey and human. This provides the opportunity to assess species differences in both renal metabolism and toxicity. Markers of toxicity must be carefully selected to discriminate between primary and secondary events in tissue injury and attention must be paid to selection of doses, the timeframe of exposure and the method of delivery. Despite the large number of variables that come into play with these systems, they have proven to be valuable tools in early screening programs.
There is increasing demand for in vitro high throughput screens for toxic potential in the earliest phases of drug discovery. Alternate detection systems that use fluorescence, luminescence, or scintillation proximity assays are much more amenable to HTS than traditional endpoints such as MTT or enzyme release. Cytotoxicity tests using the fluorescent dye Alamar Blue [23] or bioluminescent detection of ATP using firefly luciferase [24] are now being utilized for cell-based screening. Multiple endpoint analyses and kinetic analyses are possible with the advent of multicolor fluorescent detection systems [25] , fluorescent Oxygen BioSensor technology [26] and "lab on a chip" tools [27] . Single cytotoxic endpoint strategies [28] may provide valuable information within a class of compounds, but may be misleading when testing diverse compounds for diverse indications.
Because of the kidney's diversity, no single marker can be used as an indicator of renal dysfunction. A balanced approach, considering prior knowledge of compounds of similar action and the actual purpose of the screen (lead selection vs. mechanism) should be used. Sensitive methods should be used whenever simple screening methods indicate an abnormal finding or when there is a major risk of renal toxicity due to structural similarity to a known nephrotoxin or because there is a high exposure in the kidney.
( Table 1 ) lists a general scheme for preliminary studies when the target is known or suspected. This scheme can be used to screen lead compounds, select relevant species for toxicology studies and to make a first estimate of the margin of safety.
COMPARATIVE EXPOSURE OF LEAD COM-POUNDS
There is a general consensus that the internal dose of a drug, defined as the most appropriate expression of exposure (Cmax, AUC or time above a certain steady state level) of the parent drug or chemical moiety that represents the proximal toxicant, is a much better expression of dose than the dose applied externally [29, 30] . Not only does this information help to define systemic exposure and relate it to dose level and time course of a toxicology study, it also helps relate dose (exposure) to toxic effects and contributes to the assessment of human relevance. In addition, it provides information to support choice of species and treatment regimens particularly as they relate to the design of future studies. Since estimates of exposure must be developed before toxicity is formally assessed or metabolic patterns are elucidated, exposure of the parent compound is the most convenient and most appropriate surrogate marker of the internal dose. When properly used, exposure data can be correlated across species and it becomes the thread that ties information from preclinical to clinical research [31, 32] . (Table 2 ) presents a general scheme for early pilot studies. It is clear that the first studies providing maximal information are dose proportionality studies in the animal species to be used in multi-dose toxicology studies. A research bioanalytical assay must be developed early in the appropriate matrix (e.g. plasma). These studies give information on the relative degree of bioavailability, exposure, and whether exposure is proportional to dose. These initial studies will also give the first estimate of singledose toxicity and whether non-linear kinetics will come into play at high dose levels. Next, short term multi-dose studies (still in the pilot stage) are conducted to establish information on dose as related to toxicity. In a creative design, the possibility of accumulation over time and steady state plasma levels can be determined. The use of telemetry devices in animals can also provide early information on the safety pharmacology profile of the drug. All of these studies can be conducted using a minimal number of animals in a rangefinding approach. The importance of approaching drug development toxicology in this mode is important as the following information can be estimated very early -even prior to selecting development candidates: 
BIOAVAILABILITY IN TOXICOLOGY STUDIES
Optimizing bioavailability of the parent compound in early toxicology studies is paramount to designing relevant safety research based on internal dose criteria. While bioavailability is a critical factor by any route of administration, the overwhelming number of issues occurs by the oral route. (Fig. 3) describes how low oral bioavailability due to poor absorption can be addressed during safety research [33] . From a biological standpoint, other than searching for differences in strains and/or species, the most practical experimental approach is to alter the timing of feeding in relation to dosing. Dosing animals in the fed or fasted state can dramatically alter absorption [34] primarily because of the effects on gastric emptying time [35] . The presence of food in the stomach contents can alter the normal conditions in respect to pH, temperature, osmolarity and/or viscosity. In addition, the ingested volume, composition and caloric content of the meal can alter emptying time. Weakly acidic drugs, which are absorbed extensively in the stomach are more available when transit time is reduced [33] . Dethloff [36] has reviewed the physiochemical properties of xenobiotics that confer certain predictable characteristics as they relate to uptake in different areas of the gastrointestinal tract. The effect of delayed transit time in a number of chemical scenarios becomes obvious. In general, compounds with log D 7.4 values between -0.5 and 2.0 will be readily absorbed in both fed and fasted states. Log D 7.4 refers to octanol/buffer partition coefficients at pH 7.4 uncorrected for degree of ionization. Experimentally, the dog is the most convenient animal model to study fed/fasted effects as very accurate quantities of food intake and timing can be obtained [34] . Rodent models are usually avoided because of logistical problems in removing, weighing and replacing food containers on a daily basis or in actually observing animals eating specific quantities of food. Since rats consume a majority of food at night, some investigators will treat an early morning dose as the fed state while an afternoon dose is considered "more-fasted-like". However, this does introduce circadian rhythm and other variables into the experimental design [37] . Within an animal or human study, the effects of food on the gastric pH can be dramatic and variations in scheduling of feeding vs. dosing can markedly influence the outcome of the study. The basal gastric pH in normal healthy volunteers is approximately 1.8; while after meals this can rise to 3-5 [38] [39] [40] . Acyclovir, which has a relatively high water solubility in acidic media, gave different plasma levels after a heavy meal (reduced Cmax and AUC) as compared to after a light meal probably because of a marked decrease in solubility when transferred from an acidic to more neutral medium [39] . This example also supports the concept that the internal dose is more relevant than the administered dose when planning future studies or when making extrapolations across species. Studies where the exposure has been established are much easier to compare and tend to neutralize variables from experimental differences.
The most common methods of altering absorption to enhance bioavailability are through formulation efforts. When poor bioavailability is caused by dissolution ratelimited absorption, changing vehicle or carrier characteristics can lead to improvements in the dissolution of a solid and eventually result in an increase in the rate and extent of absorption [33] . Enhancement of dissolution rate can be achieved by increasing the surface area by micronization or by adding surface-active agents (e.g. tween 80) in the dosing formulation. The aqueous solubility of the compound can be increased by altering the pH environment in the vehicle thereby causing in situ salt formation or by using buffers. In addition, solute-solvent complexation reactions and solidstate solutions have been successfully used [33] . In toxicology studies, particle size reduction is the most common approach to increasing bioavailability of insoluble compounds. Micronization should be attempted first as this results in a process that can be effectively reproduced over a number of studies. Dispersion in an inert water-soluble vehicle also effectively reduces particle size. While a number have been used in pharmaceutical preparations, the most commonly used vehicles used in toxicology include carboxymethylcellulose (CMC), methylcellulose (MC), starch and polyethylene glycols (PEG). Although the primary benefit from these types of vehicles is to increase overall surface area by reducing particle size, they also result in increased wettability and a decrease in aggregation and agglomeration [33] . Initial attempts to increase bioavailability through formulation efforts should include an examination of a variety of vehicles, again with the aim of increasing the internal dose through enhanced absorption. Smith and colleagues [29] describe examples where changes in vehicles had major effects in drug absorption. With UK-52,831, a weak base with a log D 7.4 of 3.5 (highly lipophillic at physiological pH) and low water solubility, a suspension as the free base in MC resulted in negligible absorption. Since a salt form was not available for early toxicology work, satisfactory oral absorption was achieved using a PEG 400 solution. Lin [41] described two examples where formulation effects markedly altered the achieved internal dose. When L-735,524, a HIV protease inhibitor, was given orally as a suspension in 0.5% MC (pH 6.5) at a dose of 10 mg/kg, the bioavailability was 18% for the rat and 16% for the dog. When the same dose was given as a solution in 0.05M citric acid (pH 2.5), the bioavailability was 75% in the dog and 20% in the rat. Differences between species resulted from a higher gastric pH in the specific dog colony and more extensive first-pass metabolism in rats. When L-365,260, a CCK B receptor antagonist with poor water solubility was given orally as a suspension in 0.5% MC, bioavailability was 14% for the rat, 9% for the dog and 2% for the monkey. In dogs, dosing with a PEG 600 solution resulted in 80% bioavailability. PEG 600 solutions were also subsequently used in early clinical studies. Uekama, et al. [42] enhanced the oral bioavailability of several water-insoluble drugs by forming inclusion complexes with cyclodextrins. In rabbits, complexes of diazepam gave substantially higher plasma levels than the drug alone. Similar results have been reported with digitalis, phenytoin, sulfamonomethoxine, spironolactone and cinnarizine in dogs [33] . Various oil vehicles have also lead to the enhancement of absorption specifically through increased lymphatic uptake [43] . Enhancement of the bioavailability of Probucol, a highly lipophilic, water insoluble hypocholesterolemic agent, can be achieved by dosing in peanut oil to selectively target lymphatic absorption in rats [44] . The potential of intestinal lymphatic absorption of drugs is important since drugs absorbed in this manner circumvent the liver on first-pass by entering the general circulation at the junction of the left internal jugular and left subclavian veins [45] .
Another important aspect of bioavailability in toxicology studies relates directly to species differences in the distribution, metabolism and elimination of drugs. This will not be specifically addressed in this review; however, a few useful generalities should be borne in mind when animal models are selected or preliminary studies are to be conducted in one rodent strain or in one sex.
• Cytochrome P450 (CYP) drug metabolizing enzymes are differentially expressed in male and female rats. Male rats express hepatic CYP2C11, 2C13, 2A2, and 3A2 at levels 5-10 fold that of females. Female rats express CYP2C12 at 10 times male levels and 2C7, 2A1 and 2E1 at 2-3 times male levels [46] . While CYP2C is a major subfamily in rats, it is not found in humans. Therefore sex-dependent differences seen in rats do not translate to humans [47] .
• Drug metabolism by male rats can reflect human metabolism when the metabolic pathway involves CYP1A or CYP2E because of the conservation of these isoforms between rodents and humans [47] .
• Different strains of rats (i.e. Sprague-Dawley, Fischer 344, Gunn) may have different constitutive or inducible isoforms of P450 enzymes that at high doses can result in different metabolic pathways.
• Metabolic rates differ by sex in rodents: male rats faster than female rats, female mice faster than male mice [48] .
A generalized scheme incorporating both animal toxicity information and feedback from early clinical trials is shown in (Fig. 4a and 4b) . The three boxes in the upper left of the (Fig. 4a) represent a series of studies typically used as selection criteria when a series of leads are compared and contrasted to select a development candidate. The first box on Preliminary Investigations is detailed in ( Table 2) . Besides forming selection criteria for development candidates, these core studies also define the relevant species for safety assessment and help to select formulation and dosing schedules. When finished, doses for pivotal studies are determined and compound requirements for completing IND enabling studies can be accurately estimated.
Starting doses for initial clinical studies (Fig. 4b) can be estimated from the Margin of Safety developed in TK/TD studies (Fig. 4a) . (Table 3) indicates how animal toxicology information at various stages of development is used to define the Margin of Safety. During the planning stage, which could be during preliminary or early toxicology studies, using the least exposed species makes more conservative estimates. When target organ toxicity can be defined and particularly when a toxicodynamic marker is established, then the most relevant species can be used for extrapolation. When no target organ toxicity can be established in animals, safety factors may become even more important since extrapolations to humans will contain more uncertainty. The predictive quality of toxicology studies depend on selecting animal models that provide relevant information to human patient populations.
When more definitive information is developed in clinical trials on human exposure as it relates to efficacy and safety, it will be used in designing and interpreting the expanded toxicology studies.
Single Dose Escalation in Normal Subjects
•Starting Dose •1/10 -1/20 estimated effective dose or NOAEL in animals •Maximum Dose
•MTD •Pharmacokinetic determination in escalating scheme stay within acceptable margin of safety for AUC (animal data)
•Case-by-case depending on class of drug •If metric(s) for toxic effects known, can escalate higher than apparent margin of safety from animals
Multiple Dose Escalation in Normal Subjects
•MTD or equivalent AUC at NOAEL in relevant toxicology species 
CONCLUSION
In a comprehensive program for assessing the toxicity of new pharmaceutical compounds, several questions will emerge on the relevance of findings in in vitro systems and animal studies [49] . Some of these questions are:
• Are findings in animals or in vitro systems predictive for potential toxicity in humans?
• What is the mechanism of the observed toxicity?
• If there are species differences in susceptibility to certain toxicities and dose is expressed in terms of exposure are species differences dissipated?
• How do blood levels in toxicology species where toxic effects are seen compare to human exposure at therapeutic doses?
• What is the metabolic pathway of the compound in the toxicology species and is it the same in humans?
• Is the target organ of toxicity the same in several animal species?
These types of questions make it essential to develop information early in the discovery-development stage of research to create a knowledge base where prior information can be used to optimize structures of lead compounds with a greater chance of having a suitable safety profile.
Overall programs must keep three questions in mind: (1) is there a correlation between the chemical structure and potential toxicity that can be used to optimize structures of lead compounds? This information must be developed into comprehensive databases to be used with in silico chem-tox informatics systems to draw statistical correlations [3] . (2) Can specific markers of potential toxicity be identified early and used as mechanistic decision-making screens? The screens should become a part of the lead optimization program to select development candidates. (3) Will exposures in animal studies correlate with exposures observed in clinical trials? This will be important to estimate the potential therapeutic index or margin of safety of the compounds under consideration.
Information as has been outlined above can be used in a feed-back loop to predict the potential toxicity of new compounds early in the discovery stage of pharmaceutical R&D. It is anticipated that new technologies currently under development or under-going validation along with informatics advances will enable discovery and development scientists to use broad knowledge bases to enhance the safety profile of potential lead compounds in the future. 
